" class="no-js "lang="en-US"> Evonetix - Medtech Alert
Saturday, April 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Evonetix | Pharmtech Focus

Evonetix

About Evonetix

Evonetix

We are a Cambridge-based company developing a radically different approach to gene synthesis. Our desktop DNA synthesis platform will provide the ability to synthesise DNA at unprecedented accuracy, scale and speed, accelerating scientists’​ ability to use synthetic biology on a scale not currently possible.

Related Story

News

 Evonetix Commences Early Access Program for DNA Synthesised by Thermal Control on Its Semiconductor Chip | Pharmtech Focus

Evonetix Commences Early Access Program for DNA Synthesised by Thermal Control on Its Semiconductor Chip

August 17 2022

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced […]

Appointments

 Evonetix Appoints Colin McCracken as Chief Executive Officer | Pharmtech Focus

Evonetix Appoints Colin McCracken as Chief Executive Officer

June 14 2022

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the […]

Equipment

 Evonetix Granted Patent for Binary Assembly Method for Gene Synthesis | Pharmtech Focus

Evonetix Granted Patent for Binary Assembly Method for Gene Synthesis

May 10 2022

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it […]

Company Releases

 Evonetix Granted Patent for Technology Enabling Thermally-controlled DNA Synthesis | Pharmtech Focus

Evonetix Granted Patent for Technology Enabling Thermally-controlled DNA Synthesis

April 4 2022

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced […]

News

 Evonetix Granted Patent for DNA Data Storage and Retrieval Method | Pharmtech Focus

Evonetix Granted Patent for DNA Data Storage and Retrieval Method

September 22 2021

EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and […]